



## CHANGES IN INTERVENTIONS IN TYPE B ACUTE AORTIC DISSECTION PATIENTS

Poster Contributions Poster Hall B1 Sunday, March 15, 2015, 9:45 a.m.-10:30 a.m.

Session Title: Predictors and Clinical Management of Aortic Disease Abstract Category: 45. Vascular Medicine: Non Coronary Arterial Disease Presentation Number: 1191-346

Authors: <u>Sevan Misirliyan</u>, Santi Trimarchi, Firas F. Mussa, Rossella Fattori, Ali Khoynezhad, Daniel Montgomery, Arturo Evangelista, Marco Di Eusanio, Eva Kline-Rogers, Truls Myrmel, Khaled Abdul-Nour, G. Michael Deeb, Eric Isselbacher, Christoph Nienaber, Kim Eagle, Himanshu Patel, University of Michigan, Ann Arbor, MI, USA

Background: Patients with complicated Type B Acute Aortic Dissection (TBAAD) should receive an intervention.

**Methods:** TBAAD patients enrolled in the International Registry of Acute Aortic Dissection were split by time (T1=1996-2001, T2=2002-2007, N=, T3=2008-2013) and stratified by those who received interventions.

**Results:** No difference was noted in age, gender, or patient history. Overall, TBAAD patients received more interventions over time (29.7% T1, N=149; 39.2% T2, N=203; 39.5% T3, N=181; p=0.001, trend p=0.001). TEVAR and/or fenestration increased (12.6% T1, N=63; 25.1% T2, N=130; 32.3% T3, N=148; p<0.001, trend p<0.001) while surgery decreased (17.2% T1, N=86; 14.1% T2, N=73; 7.2% T3, N=33; p<0.001, trend p<0.001). Interventional in-hospital mortality did not differ (19.5% T1, 10.3% T2, 13.8% T3, p=0.052, trend p=0.177). In a climate of increasing interventions, overall TBAAD in-hospital mortality did not change (12.4% T1, 8.1% T2, 11.8% T3, p=0.058, trend p=0.722). Later time periods demonstrated shorter median length of stay (16.0 T1, 14.0 T2, 13.0 T3, p<0.001) and lower post-discharge mortality (figure).

**Conclusion:** We identified divergent trends in TBAAD management. Early mortality did not change as interventions increased and postdischarge survival improved. Despite the survival advantages of TEVAR v. surgery, complicated TBAAD carries high risk. With recent evidence showing improved long-term survival with TEVAR, our data supports an increasing use of this technology.

